Market News & Trends
Appili Therapeutics Signs $3-Million Grant to Develop Antibiotics That Target Superbugs
Appili Therapeutics Inc. recently announced the United States Department of Defense, (DOD) Congressionally Directed Medical Research Programs, Peer Reviewed Medical Research Program (PRMRP) has completed…
Amicus Therapeutics & Brammer Bio Enter Strategic Development & Manufacturing Collaboration
Amicus Therapeutics, Inc. has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific. Thermo Fisher, a best-in-class contract development and manufacturing organization (CDMO) with…
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell
Therapeutics Solutions International, Inc. recently announced signing of a license agreement providing exclusive rights to a patented adult stem cell for development of therapeutics in…
Y-mAbs Announces Recruitment Status for Pivotal Trials
Y-mAbs Therapeutics, Inc. recently announced the status of patient recruitment for the company’s two pivotal Phase 2 trials, one for omburtamab for the treatment of…
Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial
Verrica Pharmaceuticals Inc. recently announced that the first patient has been enrolled in the company’s Phase 2 ‘CARE’ clinical trial evaluating the optimal dose regimen,…
Esperion & Oberland Capital Announce $200-Million Agreement
Esperion recently announced a $200 million capped, tiered, revenue-based funding agreement on net revenues of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.…
Seelos Therapeutics Announces Acquisition of Exclusive Worldwide License of Gene Therapy Program
Seelos Therapeutics, Inc. recently announced the exclusive worldwide licensing of a gene therapy program targeting the regulation of the SNCA gene, which encodes alpha-synuclein expression, …
SunGen Pharma Announces Partnership With Athenex Pharmaceutical
SunGen Pharma recently announced to launch Bivalirudin for Injection in the near future through their joint venture Peterson Athenex with Athenex Pharmaceuticals. This tentatively approved…
Wave Life Sciences Announces Initiation of Phase 2/3 Clinical Trial
Wave Life Sciences Ltd. recently announced the initiation of DYSTANCE 51, the Phase 2/3 efficacy and safety clinical trial of suvodirsen, an investigational stereopure oligonucleotide…
Atossa Genetics Preliminary Phase 2 Study Achieves Primary Endpoint
Atossa Genetics Inc. recently announced that a preliminary analysis from its recently completed Phase 2 study of the company’s proprietary 20-mg daily topical Z Endoxifen…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….